Kristine Mørchs bilde

Kristine Mørch

Førsteamanuensis, Leder nasjonalt senter for tropiske infeksjonssykdommer, infeksjonsseksjonen, medisinsk avdeling, Haukeland universitetssykehus
  • E-postkristine.morch@uib.no
  • Telefon004755975660
  • Besøksadresse
    Medisinsk avdeling, Haukeland universitetssykehus
    5021 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen

Kristine Mørch, MD, PhD er leder ved Nationalt senter for tropiske infeksjonssykdommer ved infeksjonsseksjonen, medisinsk avdeling, Haukeland universitetssykehus. Hun er også førsteamanuensis ved klinisk institutt ved Universitetet i Bergen. Hennes forskningsinteresser er innenfor tropiske infeksjonssykdommer, spesielt akutt febersykdom og malaria, samt Giardia infeksjon med fokus på metronidazolresistens og behandling.

Vitenskapelig artikkel
  • Vis forfatter(e) (2024). Predominance of multidrug-resistant Salmonella Typhi genotype 4.3.1 with low-level ciprofloxacin resistance in Zanzibar. PLoS Neglected Tropical Diseases.
  • Vis forfatter(e) (2024). Ein mann i 60-åra med livstrugande febersjukdom etter utanlandsreise. Tidsskrift for Den norske legeforening.
  • Vis forfatter(e) (2023). Clinical features and risk factors for death in acute undifferentiated fever: A prospective observational study in rural community hospitals in six states of India. Transactions of the Royal Society of Tropical Medicine and Hygiene. 91-101.
  • Vis forfatter(e) (2022). No difference in serum levels of B-cell activating receptor and antibodies against cytolethal distending toxin B and flagellin in post-infectious irritable bowel syndrome and chronic fatigue syndrome after Giardia infection. Journal of Gastroenterology and Hepatology Open (JGH Open). 185-188.
  • Vis forfatter(e) (2022). Malaria prevalence and performance of diagnostic tests among patients hospitalized with acute undifferentiated fever in Zanzibar. Malaria Journal. 1-8.
  • Vis forfatter(e) (2021). Schistosomiasis hos norske studenter etter opphold i Afrika. Tidsskrift for Den norske legeforening. 243-247.
  • Vis forfatter(e) (2021). Presence of interferon-λ 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. Scandinavian Journal of Gastroenterology. 849-854.
  • Vis forfatter(e) (2021). Leishmaniasis i Norge. Tidsskrift for Den norske legeforening. 1-9.
  • Vis forfatter(e) (2021). Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: A TropNet Study. Clinical Infectious Diseases. 1517-1523.
  • Vis forfatter(e) (2021). Antibiotics for gastroenteritis in general practice and out-of-hours services in Norway 2006-15. Family Practice. 19-25.
  • Vis forfatter(e) (2020). The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection. PLOS ONE. 1-16.
  • Vis forfatter(e) (2020). Giardiasis treatment: an update with a focus on refractory disease. Current Opinion in Infectious Diseases. 355-364.
  • Vis forfatter(e) (2020). Detection of remaining Plasmodium DNA and gametocytes during follow up after curative malaria treatment among returned travellers in Norway. Malaria Journal.
  • Vis forfatter(e) (2020). Bacteraemia, malaria, and case fatality among children hospitalized with fever in Dar es Salaam, Tanzania. Frontiers in Microbiology. 1-10.
  • Vis forfatter(e) (2019). En mann i 80-årene med leddgikt og vedvarende feber. Tidsskrift for Den norske legeforening. 6 sider.
  • Vis forfatter(e) (2019). Assessment of malaria real-time PCR methods and application with focus on lowlevel parasitaemia. PLOS ONE. 1-15.
  • Vis forfatter(e) (2017). Severe malaria in Europe: an 8-year multi-centre observational study. Malaria Journal. 1-11.
  • Vis forfatter(e) (2017). Serovar prevalence of leptospira in semirural India and the development of an igm-based indirect ELISA. Journal of Infection in Developing Countries. 234-241.
  • Vis forfatter(e) (2017). Schistosomiasis in european travelers and migrants: Analysis of 14 years tropnet surveillance data. American Journal of Tropical Medicine and Hygiene. 567-574.
  • Vis forfatter(e) (2017). Giardia-specific cellular immune responses in post-giardiasis chronic fatigue syndrome. BMC Immunology. 1-8.
  • Vis forfatter(e) (2017). Acute undifferentiated fever in India: A multicentre study of aetiology and diagnostic accuracy. BMC Infectious Diseases. 1-11.
  • Vis forfatter(e) (2016). Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. Scandinavian Journal of Gastroenterology. 337-343.
  • Vis forfatter(e) (2016). Postinfectious and sporadic functional gastrointestinal disorders have different prevalences and rates of overlap: results from a controlled cohort study 3 years after acute giardiasis. Neurogastroenterology and Motility. 1561-1569.
  • Vis forfatter(e) (2016). A high malaria prevalence identified by PCR among patients with acute undifferentiated fever in India. PLOS ONE.
  • Vis forfatter(e) (2015). Schistosomiasis in pregnant travelers: A case series. Journal of Travel Medicine (JTM). 94-98.
  • Vis forfatter(e) (2015). Intravenous artesunate reduces parasite clearance time, duration of intensive care, and hospital treatment in patients with severe malaria in Europe: The TropNet severe malaria study. Clinical Infectious Diseases. 1441-1444.
  • Vis forfatter(e) (2015). Beredskap ved alvorlig malaria. Tidsskrift for Den norske legeforening. 533-535.
  • Vis forfatter(e) (2014). Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology. 2131-2139.
  • Vis forfatter(e) (2014). Irritable bowel syndrome and chronic fatigue 6 years after Giardia infection: A controlled prospective cohort study. Clinical Infectious Diseases. 1394-1400.
  • Vis forfatter(e) (2014). A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. PLOS ONE.
  • Vis forfatter(e) (2013). Fever in the tropics: aetiology and case-fatality - a prospective observational study in a tertiary care hospital in South India. BMC Infectious Diseases. 8 sider.
  • Vis forfatter(e) (2013). Chronic fatigue syndrome 5 years after giardiasis: differential diagnoses, characteristics and natural course. BMC Gastroenterology. 17 sider.
  • Vis forfatter(e) (2013). A novel, single-amplification PCR targeting mitochondrial genome highly sensitive and specific in diagnosing malaria among returned travellers in Bergen, Norway. Malaria Journal. 8 sider.
  • Vis forfatter(e) (2012). The impact of atopic disease on the risk of post-infectious fatigue and irritable bowel syndrome 3 years after Giardia infection. A historic cohort study. Scandinavian Journal of Gastroenterology. 956-961.
  • Vis forfatter(e) (2012). PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. BMC Medical Genetics. 7 sider.
  • Vis forfatter(e) (2012). Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study. Gut. 214-219.
  • Vis forfatter(e) (2012). Impact of Obesity on the Bioavailability of Peginterferon-alpha 2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3. PLOS ONE. 7 sider.
  • Vis forfatter(e) (2012). Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLOS ONE. 7 sider.
  • Vis forfatter(e) (2012). Immunophenotyping in post-giardiasis functional gastrointestinal disease and chronic fatigue syndrome. BMC Infectious Diseases. 258.
  • Vis forfatter(e) (2012). Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection. European Journal of Clinical Microbiology and Infectious Diseases. 1631-1635.
  • Vis forfatter(e) (2011). Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection. Journal of Viral Hepatitis. 245-251.
  • Vis forfatter(e) (2011). Intravenous Artesunate for Severe Malaria in Travelers, Europe. Emerging Infectious Diseases. 771-777.
  • Vis forfatter(e) (2011). Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. Journal of Infectious Diseases. 1748-1752.
  • Vis forfatter(e) (2011). Hepatitis C treatment response kinetics and impact of baseline predictors. Journal of Viral Hepatitis. 1-7.
  • Vis forfatter(e) (2010). Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations? Clinical Infectious Diseases. E22-E25.
  • Vis forfatter(e) (2010). Giardiasis: the ever-present threat of a neglected disease. Current Drug Targets - Infectious Disorders. 329-348.
  • Vis forfatter(e) (2010). Giardiasis ? why do the symptoms sometimes never stop? Trends in Parasitology. 75-82.
  • Vis forfatter(e) (2010). Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 430-435.
  • Vis forfatter(e) (2009). Severity of Giardia infection associated with post-infectious fatigue and abdominal symptoms two years after. BMC Infectious Diseases.
  • Vis forfatter(e) (2009). High rate of fatigue and abdominal symptoms 2 years after an outbreak of giardiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene. 530-532.
  • Vis forfatter(e) (2008). Treatment-ladder and genetic characterisation of parasites in refractory giardiasis after an outbreak in Norway. Journal of Infection. 268-273.
  • Vis forfatter(e) (2008). Sensitivity of a Giardia antigen test in persistent giardiasis following an extensive outbreak. Clinical Microbiology and Infection (CMI). 1069-1071.
  • Vis forfatter(e) (2008). Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. 1837-1835.
  • Vis forfatter(e) (2008). Effects of albendazole/metronidazole or tetracycline/folate treatments on persisting symptoms after Giardia infection: A randomized open clinical trial. Scandinavian Journal of Infectious Diseases. 517-522.
  • Vis forfatter(e) (2022). Apekopper i Norge. Tidsskrift for Den norske legeforening.
  • Vis forfatter(e) (2015). Hund som Giardia-kilde i Bergen i 2004 - barking up the wrong tree? Tidsskrift for Den norske legeforening. 1718-1720.
  • Vis forfatter(e) (2011). Early determination of Hepatitis C virus RNA may help to decide the duration of therapy for chronic Hepatitis C virus genotype 2/3 infection. Hepatology. 1067-1068.
  • Vis forfatter(e) (2008). Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology. 695-695.
Short communication
  • Vis forfatter(e) (2015). Severe human Babesia divergens infection in Norway. International Journal of Infectious Diseases. 37-38.
  • Vis forfatter(e) (2013). Utveksling av helsepersonell mellom Bergen og Zanzibar. Tidsskrift for Den norske legeforening. 187-189.
  • Vis forfatter(e) (2019). PCR based Malaria diagnostics – Method development and application.
  • Vis forfatter(e) (2010). Giardiasis - with emphasis on treatment and post-infectious manifestations.
  • Vis forfatter(e) (2012). Impact of Inosine Triphosphatase (ITPA) Gene Variants on Anemia, Ribavirin Concentrations, and Outcome During Therapy for HCV Genotype 2/3. Hepatology. 1023A-1023A.
  • Vis forfatter(e) (2012). A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. Hepatology. 682A-683A.
  • Vis forfatter(e) (2011). Impact of obesity on the bioavailability of peginterferon-alpha 2A and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. Hepatology. 1321A-1322A.
  • Vis forfatter(e) (2008). Twelve weeks of treatment is insufficient for HCV genotype 2 and 3 infected patients with steatosis. Journal of Hepatology. S314-S315.
  • Vis forfatter(e) (2008). Ribavirin concentration at week four is an independend predictor for sustained virological response after treatment of hepatitis C genotype 2/3 (NORDynamic trial). Journal of Hepatology. S6-S7.
  • Vis forfatter(e) (2007). Peginterferon alfa-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2/3: The nordynamic trial. Hepatology. 815A-816A.
  • Vis forfatter(e) (2007). Comparison of peginterferon alpha-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2/3: The nordynamic trial. Journal of Hepatology. S229-S229.
  • Vis forfatter(e) (2018). Schistosomiasis in Norwegian medical students .
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2010). Giardiasis - why do the symptoms sometimes never stop? Trends in Parasitology. 75-82.

Se fullstendig oversikt over publikasjoner i CRIStin.